SCHEDULE: Lytton Boosts TELA Bio Stake to 8.5%

Laurence W. Lytton has increased his beneficial ownership in TELA Bio, Inc. to 8.5% of the common stock outstanding.

Summary

• Laurence W. Lytton reported beneficial ownership of 3,424,191 shares of TELA Bio, Inc. Common Stock.
• This ownership represents 8.5% of the company's outstanding Common Stock.
• The shares consist of 2,724,191 shares of Common Stock and 700,000 shares issuable from outstanding warrants.
• The percentage is based on 39,616,440 shares of Common Stock outstanding as of August 4, 2025, as reported in the Issuer's Form 10-Q for the quarter ended June 30, 2025.
• Lytton holds sole voting and sole dispositive power over all 3,424,191 shares.
• The acquisition of these securities was not for the purpose of changing or influencing control of the issuer, indicating a passive investment.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of increased beneficial ownership. While not directly impacting company operations, a larger stake by an individual investor can be perceived positively as a vote of confidence, especially when declared as a passive investment.

Positives

• Increased stake by a significant individual investor may signal confidence in the company's long-term prospects.
• The investor's certification indicates a passive investment, suggesting no immediate intent to influence control, which can provide stability.

Negatives

• NA

Risks

• NA

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reflects an individual investor's increased stake in TELA Bio, Inc., a company operating in the healthcare and medical device sector. Such ownership disclosures are common and provide transparency into significant investor positions, but do not inherently reflect broader industry trends beyond the specific company's investor base.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant individual investor's stake, potentially influencing investor sentiment.
• Company Management: Awareness of a substantial passive investor holding 8.5% of outstanding shares.

Key Dates

Keywords

TELA Bio, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investor Stake, Healthcare, Medical Devices